Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 3, 2014Organic Process Research & Development

Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin

View Full Paper
Ask AI
Bookmark
Share

Authors

DBDavid J. BernhardsonPfizer (United States)TBThomas A. BrandtPfizer (United States)CHCatherine A. HulfordPfizer (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bernhardson et al. (2014) studied this question.

synapsesocial.com/papers/6aae3c42a2c879582b43bcachttps://doi.org/10.1021/op400289z
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chemoenzymic Approaches to the Preparation of 5-C-(Hydroxymethyl)hexoses1997 · 28 citations
  2. 2Development of the Renal Glucose Reabsorption Inhibitors: A New Mechanism for the Pharmacotherapy of Diabetes Mellitus Type 22009 · 155 citations
  3. 3Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes2008 · 635 citations
  4. 4Direct, Mild, and Selective Synthesis of Unprotected Dialdo‐Glycosides2006 · 66 citations
  5. 5Silica-bound sulfonic acid catalysts1989 · 81 citations